Hexarelin
Overview
A synthetic hexapeptide growth hormone secretagogue with the highest GH-releasing potency among GHRPs. Hexarelin binds both GHS-R1a and CD36 (scavenger receptor), giving it unique cardiovascular properties independent of GH release.
Mechanism of Action
It exhibits cardioprotective effects through reduced atherosclerotic plaque formation and improved cardiac contractility via direct myocardial receptor activation.
Research Summary & Key Findings
Clinical trials demonstrated the most potent acute GH release among GHRPs. Unique CD36-mediated cardiovascular effects include improved cardiac output in heart failure patients and reduced lipid accumulation in macrophages. Subject to significant tachyphylaxis with chronic dosing, limiting long-term utility for GH augmentation (Broglio et al., J Endocrinol Invest, 2005).
Clinical Status
Hexarelin is in the investigational stage. While preclinical and early-phase data exist, it has not received regulatory approval for clinical use in the United States.
Administration Routes
References
Primary literature
- PubMed — "Hexarelin"
Peer-reviewed literature indexed by the National Library of Medicine.
- ClinicalTrials.gov — "Hexarelin"
Registered interventional and observational studies, including status and phase.
- PubChem — "Hexarelin"
Chemical structure, molecular properties, and bioactivity data.
Study-level citations for this compound are being verified against the primary sources before publication. The database queries above return the current indexed literature in the meantime.
Related Peptides in Hormone
CJC-1295
In Clinical TrialsA synthetic analog of growth hormone-releasing hormone (GHRH) with a Drug Affinity Complex (DAC) that binds to albumin, ...
View detailsIpamorelin
In Clinical TrialsA highly selective growth hormone secretagogue that acts on ghrelin/GHS receptors in the pituitary gland to stimulate GH...
View detailsSermorelin
FDA ApprovedA synthetic 29-amino acid analog of GHRH representing the shortest fully functional fragment of the native 44-amino acid...
View detailsTesamorelin (Egrifta)
FDA ApprovedA synthetic GHRH analog consisting of the 44-amino acid sequence of human GHRH with a trans-3-hexenoic acid modification...
View detailsStart Your Consultation
Get an AI-proposed Hexarelin protocol reviewed by a physician in our network.
Start Your ConsultationFind a Pharmacy
Browse PCAB-accredited and FDA 503B-registered compounding pharmacies that supply Hexarelin.
Pharmacy DirectoryJoin the Association
Access exclusive peptide protocols, provider resources, and community support.
List Your PracticeDisclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol. See our editorial policy for how this content is produced and reviewed.